Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer

A paradigm shift is currently underway on the relationship between cancer treatment markers and therapies. Labyrinthin is a prime example of such a marker because it is a pan-cancer target for adenocarcinomas. This movement supports the idea that we must change our thinking from various cancer types...

Descripción completa

Detalles Bibliográficos
Autores principales: Radosevich, James A, Babich, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844151/
https://www.ncbi.nlm.nih.gov/pubmed/31807015
http://dx.doi.org/10.2147/OTT.S220445
_version_ 1783468379657469952
author Radosevich, James A
Babich, Michael
author_facet Radosevich, James A
Babich, Michael
author_sort Radosevich, James A
collection PubMed
description A paradigm shift is currently underway on the relationship between cancer treatment markers and therapies. Labyrinthin is a prime example of such a marker because it is a pan-cancer target for adenocarcinomas. This movement supports the idea that we must change our thinking from various cancer types (eg, lung, breast, colon) to “cancer arising” in a given tissue or organ. In doing so, this would further support the efforts toward pan-treatments rather than organ-specific treatments.
format Online
Article
Text
id pubmed-6844151
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-68441512019-12-05 Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer Radosevich, James A Babich, Michael Onco Targets Ther Perspectives A paradigm shift is currently underway on the relationship between cancer treatment markers and therapies. Labyrinthin is a prime example of such a marker because it is a pan-cancer target for adenocarcinomas. This movement supports the idea that we must change our thinking from various cancer types (eg, lung, breast, colon) to “cancer arising” in a given tissue or organ. In doing so, this would further support the efforts toward pan-treatments rather than organ-specific treatments. Dove 2019-11-06 /pmc/articles/PMC6844151/ /pubmed/31807015 http://dx.doi.org/10.2147/OTT.S220445 Text en © 2019 Radosevich and Babich. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Perspectives
Radosevich, James A
Babich, Michael
Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
title Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
title_full Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
title_fullStr Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
title_full_unstemmed Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
title_short Labyrinthin, The Tumor Marker Recognized By MCA 44-3A6: A Case For Pan-Tumor Markers As Targets To Treat Cancer
title_sort labyrinthin, the tumor marker recognized by mca 44-3a6: a case for pan-tumor markers as targets to treat cancer
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844151/
https://www.ncbi.nlm.nih.gov/pubmed/31807015
http://dx.doi.org/10.2147/OTT.S220445
work_keys_str_mv AT radosevichjamesa labyrinthinthetumormarkerrecognizedbymca443a6acaseforpantumormarkersastargetstotreatcancer
AT babichmichael labyrinthinthetumormarkerrecognizedbymca443a6acaseforpantumormarkersastargetstotreatcancer

Ejemplares similares